Authors and Disclosures
Keiichiro Moria,b, Manuela Schmidingera, Fahad Quhala,c, Shin Egawab, Shahrokh F. Shariata,d,e,f,g,h,i and Viktor Grünwaldj
aDepartment of Urology, Medical University of Vienna, Vienna, Austria, bDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan, cDepartment of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia, dDivision of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan, eInstitute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia, fDepartment of Urology, Weill Cornell Medical College, New York, New York, USA, gDepartment of Urology, University of Texas Southwestern, Dallas, Texas, USA, hKarl Landsteiner Institute of Urology and Andrology, Vienna, Austria, iDepartment of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic and jClinic for medical oncology and Clinic for Urology, West German Cancer Center Essen, University Hospital Essen, Essen, Germany
Correspondence to
Viktor Grünwald, University Hospital Essen, West-German Cancer Center Essen, Clinic for Medical Oncology and Clinic for Urology, Hufelandstraße 55, D-45147 Essen, Germany. Tel: +49 201/723 2637; fax: +49 201/723 5851; e-mail: viktor.gruenwald@uk-essen.de
Conflicts of interest
V.G. reports grants, personal fees and nonfinancial support from Astra Zeneca, grants, personal fees and nonfinancial support from Bristol-Myers Squibb, personal fees from MSD Sharp & Dohme, grants, personal fees and nonfinancial support from Ipsen, personal fees from Merck Serono, grants, personal fees and nonfinancial support from Pfizer, personal fees from EUSAPharm, personal fees from Novartis, personal fees from Eisai; grants and nonfinancial support from Astra Zeneca, grants, personal fees and nonfinancial support from Bristol-Myers Squibb, personal fees and nonfinancial support from Bayer, grants and personal fees from MSD Sharp & Dohme, personal fees from Roche, personal fees from Janssen-Cilag, personal fees from Asklepios Clinic, personal fees from Diakonie Clinic, personal fees from Lilly, personal fees from PharmaMar, personal fees from Dortmund Hospital, personal fees from Clinic of Oldenburg, personal fees from Onkowissen, grants from Novartis, personal fees from Janssen-Cilag, grants and personal fees from MSD Sharp & Dohme.S.S. owns or co-owns the following patents: Methods to determine prognosis after therapy for prostate cancer. Granted 2002–09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003–06-19. Prognostic methods for patients with prostatic disease. Granted 2004–08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010–07-20. He has a consulting or advisory role for the following: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Jansen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia, Sanofi, Takeda, Urogen, Wolff.